September 25, 2025
Verano to Report Third Quarter 2025 Financial Results on October 29, 2025
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a…
Pharmaceuticals, Biotechnology and Life Sciences
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a…
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing…
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.,…
Transaction expected to close on October 7, 2025LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) — Verona Pharma…
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B.…
– 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% – – 53% progression-free survival…
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in…
Breakthrough Therapies and Life Sciences Leadership Take Center Stage October 1–2 in Newport BeachLOS ANGELES, Sept. 24, 2025 (GLOBE NEWSWIRE)…
H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER1 and on a like-for-like basis2, mainly…